Advertisement News Archives - Page 2513 of 5234 - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

August 28, 2026

FDA to review Kowa Pharmaceuticals’ NDA for glaucoma eye drop K-911

The US Food and Drug Administration (FDA) is set to review Kowa Pharmaceuticals America’s new drug application (NDA) for K-911, an investigational once-daily eye drop aimed at reducing intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients.

FDA to review Kowa Pharmaceuticals’ NDA for glaucoma eye drop K-911